vs
Side-by-side financial comparison of Claritev Corp (CTEV) and HUTCHMED (China) Ltd (HCM). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $246.6M, roughly 1.1× Claritev Corp). HUTCHMED (China) Ltd runs the higher net margin — 0.7% vs -32.7%, a 33.4% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -16.5%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $3.4M).
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
CTEV vs HCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $270.8M |
| Net Profit | $-80.6M | $2.0M |
| Gross Margin | — | 37.7% |
| Operating Margin | -3.1% | -13.2% |
| Net Margin | -32.7% | 0.7% |
| Revenue YoY | 6.2% | -16.5% |
| Net Profit YoY | 41.6% | -83.6% |
| EPS (diluted) | $-4.88 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $270.8M | ||
| Q3 25 | $246.0M | — | ||
| Q2 25 | $241.6M | $277.7M | ||
| Q1 25 | $231.3M | $324.5M | ||
| Q4 24 | $232.1M | — | ||
| Q3 24 | $230.5M | — | ||
| Q2 24 | $233.5M | $305.7M | ||
| Q1 24 | $234.5M | — |
| Q4 25 | $-80.6M | $2.0M | ||
| Q3 25 | $-69.8M | — | ||
| Q2 25 | $-62.6M | $455.0M | ||
| Q1 25 | $-71.3M | $11.9M | ||
| Q4 24 | $-138.0M | — | ||
| Q3 24 | $-391.4M | — | ||
| Q2 24 | $-576.7M | $25.8M | ||
| Q1 24 | $-539.7M | — |
| Q4 25 | — | 37.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 48.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 41.1% | ||
| Q1 24 | — | — |
| Q4 25 | -3.1% | -13.2% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 6.9% | -1.3% | ||
| Q1 25 | 4.2% | -5.0% | ||
| Q4 24 | -17.8% | — | ||
| Q3 24 | -146.7% | — | ||
| Q2 24 | -224.4% | -9.0% | ||
| Q1 24 | -207.4% | — |
| Q4 25 | -32.7% | 0.7% | ||
| Q3 25 | -28.4% | — | ||
| Q2 25 | -25.9% | 163.8% | ||
| Q1 25 | -30.8% | 3.7% | ||
| Q4 24 | -59.4% | — | ||
| Q3 24 | -169.8% | — | ||
| Q2 24 | -247.0% | 8.4% | ||
| Q1 24 | -230.1% | — |
| Q4 25 | $-4.88 | $0.00 | ||
| Q3 25 | $-4.23 | — | ||
| Q2 25 | $-3.81 | $0.52 | ||
| Q1 25 | $-4.38 | $0.01 | ||
| Q4 24 | $-8.49 | — | ||
| Q3 24 | $-24.25 | — | ||
| Q2 24 | $-35.78 | $0.03 | ||
| Q1 24 | $-33.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $1.4B |
| Total DebtLower is stronger | $4.6B | $93.2M |
| Stockholders' EquityBook value | $-173.9M | $1.2B |
| Total Assets | $4.9B | $1.8B |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $1.4B | ||
| Q3 25 | $39.2M | — | ||
| Q2 25 | $56.4M | $1.4B | ||
| Q1 25 | $23.1M | $836.1M | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $86.6M | — | ||
| Q2 24 | $48.8M | $802.5M | ||
| Q1 24 | $58.7M | — |
| Q4 25 | $4.6B | $93.2M | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | $93.4M | ||
| Q1 25 | $4.5B | $82.8M | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | $82.1M | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $1.2B | ||
| Q3 25 | $-101.8M | — | ||
| Q2 25 | $-39.9M | $1.2B | ||
| Q1 25 | $14.8M | $759.9M | ||
| Q4 24 | $84.0M | — | ||
| Q3 24 | $207.6M | — | ||
| Q2 24 | $603.4M | $740.1M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $4.9B | $1.8B | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.1B | $1.8B | ||
| Q1 25 | $5.1B | $1.3B | ||
| Q4 24 | $5.2B | — | ||
| Q3 24 | $5.3B | — | ||
| Q2 24 | $5.7B | $1.3B | ||
| Q1 24 | $6.4B | — |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | 304.87× | 0.11× | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | 0.11× | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $8.2M |
| Free Cash FlowOCF − Capex | $36.4M | $3.4M |
| FCF MarginFCF / Revenue | 14.8% | 1.2% |
| Capex IntensityCapex / Revenue | 12.1% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 4.21× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $-96.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $8.2M | ||
| Q3 25 | $19.9M | — | ||
| Q2 25 | $61.2M | $-72.9M | ||
| Q1 25 | $-30.1M | $40.3M | ||
| Q4 24 | $-33.4M | — | ||
| Q3 24 | $72.8M | — | ||
| Q2 24 | $18.5M | $-39.8M | ||
| Q1 24 | $49.7M | — |
| Q4 25 | $36.4M | $3.4M | ||
| Q3 25 | $-16.3M | — | ||
| Q2 25 | $36.6M | $-82.2M | ||
| Q1 25 | $-68.9M | $32.5M | ||
| Q4 24 | $-63.8M | — | ||
| Q3 24 | $41.1M | — | ||
| Q2 24 | $-7.0M | $-49.9M | ||
| Q1 24 | $19.2M | — |
| Q4 25 | 14.8% | 1.2% | ||
| Q3 25 | -6.6% | — | ||
| Q2 25 | 15.2% | -29.6% | ||
| Q1 25 | -29.8% | 10.0% | ||
| Q4 24 | -27.5% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | -3.0% | -16.3% | ||
| Q1 24 | 8.2% | — |
| Q4 25 | 12.1% | 1.8% | ||
| Q3 25 | 14.7% | — | ||
| Q2 25 | 10.2% | 3.3% | ||
| Q1 25 | 16.8% | 2.4% | ||
| Q4 24 | 13.1% | — | ||
| Q3 24 | 13.8% | — | ||
| Q2 24 | 10.9% | 3.3% | ||
| Q1 24 | 13.0% | — |
| Q4 25 | — | 4.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.16× | ||
| Q1 25 | — | 3.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.54× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
